Brief: Ocugen Gets EMA Backing on OCU410ST Approval Pathway for Stargardt Gene Therapy
13/08/2025 12:35
Aug 13 (Reuters) - Ocugen Inc OCGN.O: OCUGEN, INC. ANNOUNCES POSITIVE SCIENTIFIC ADVICE FROM THE EUROPEAN MEDICINES AGENCY RELATED TO THE APPROVAL PATHWAY FOR OCU410ST—MODIFIER GENE THERAPY FOR STARGARDT DISEASE Source text: ID:nGNXb1M54S Further company coverage: OCGN.O ((Reuters.Briefs@thomsonreuters.com;))